Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders.
Functional brain imaging using 18F fluorodeoxyglucose (FDG) and positron emission tomography (PET) has greatly enhanced our understanding of brain function both in normal conditions as well as in a wide variety of neuropsychiatric disorders. We review the uses of FDG PET in the diagnosis, management, and follow-up of patients with neuropsychiatric disorders. This article will also explore what FDG-PET imaging has revealed in these neuropsychiatric disorders and how these findings relate to both research and clinical applications.
Newberg
Andrew
A
Division of Nuclear Medicine, The Hospital of the University of Pennsylvania, Philadelphia 19104, USA.
Alavi
Abass
A
Reivich
Martin
M
D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000000981:diagnostic imaging* / Q000503:physiopathology; D001927:Brain Diseases / Q000000981:diagnostic imaging* / Q000503:physiopathology; D019788:Fluorodeoxyglucose F18; D006801:Humans; D001523:Mental Disorders / Q000000981:diagnostic imaging* / Q000503:physiopathology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals
D001786:Blood Glucose; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18